The Role of Nephrectomy in Metastatic Renal Cell Carcinoma

  • E. A. Klein
Conference paper

Abstract

Radical nephrectomy is well established as the standard treatment for localized renal cell carcinoma. Nephrectomy is the only known curative therapy for this tumor. The role of radical nephrectomy in the management of metastatic renal cell carcinoma is controversial and has come under increased scrutiny in the past several years with the development of immunotherapy, which has the potential to cure systemic renal cell carcinoma. Thus, immunotherapy combined with radical nephrectomy has the potential to cure patients with metastatic disease.

Keywords

Toxicity Anemia Interferon Hypercalcemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johnson DE, Kaesler KE, Samuels ML (1975) Is nephrectomy justified in patients with metastatic renal cell carcinoma. J Urol 114: 27PubMedGoogle Scholar
  2. 2.
    Klugo RC, Detmers M, Stiles RE et al. (1977) Aggressive versus conservative management of stage IV renal cell carcinoma. J Urol 118: 244PubMedGoogle Scholar
  3. 3.
    Montie JE, Stewart BH, Straffon RA et al. (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117: 272PubMedGoogle Scholar
  4. 4.
    Patel NP, Lavengood RW (1978) Renal cell carcinoma: natural history and results of treatment. J Urol 119: 722PubMedGoogle Scholar
  5. 5.
    Frank J (1992) Nephrectomy in metastatic renal cell carcinoma. J Urol 147: 421AGoogle Scholar
  6. 6.
    Tolia BM, Whitmore WF (1975) Solitary metastases from renal cell carcinoma. J Urol 114: 836PubMedGoogle Scholar
  7. 7.
    Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97: 973PubMedGoogle Scholar
  8. 8.
    deKernion JB, Ramming KD, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120: 148Google Scholar
  9. 9.
    O’Dea MJ, Zincke H, Utz DC et al. (1978) The treatment of renal cell carcinoma with solitary metastases. J Urol 120: 540PubMedGoogle Scholar
  10. 10.
    Bukowski R, Murthy S, Klein EA et al. Tumor infiltrating lymphocytes in metastatic renal cell carcinoma: the Cleveland clinic experience. In: Klein EA, Bukowski R, Finke J (eds) The immunobiology of renal cell carcinoma, (in press)Google Scholar
  11. 11.
    Belldegrun A, Webb DE, Austin HA et al. (1989) Renal toxicity of interleukin-II administration in patients with metastatic renal cell cancer: effect of pretherapy nephrectomy. J Urol 141: 499PubMedGoogle Scholar
  12. 12.
    Robertson CN, Linehan WM, Pass HI et al. (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma, treated with adoptive immunotherapy with interleukin-II or interleukin-II plus lymphokine-activated killer cells. J Urol 144: 614PubMedGoogle Scholar
  13. 13.
    Fleischmann J, Kim B (1991) Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145: 938PubMedGoogle Scholar
  14. 14.
    Spencer WF, Linehan WM, Walther MM et al. (1992) Immunotherapy with IL-2 and alpha interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol 147: 24PubMedGoogle Scholar
  15. 15.
    Fowler JE (1987) Urol Clin North Am 14: 745–756Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • E. A. Klein
    • 1
  1. 1.Section of Urologic OncologyCleveland Clinic FoundationClevelandUSA

Personalised recommendations